Ultrasound screening of ovarian cancer (2024)

Baümler, M., Gallant, D., Druckmann, R. (2020). Ultrasound screening of ovarian cancer. Hormone Molecular Biology and Clinical Investigation, 41(3), Article 20190022. https://doi.org/10.1515/hmbci-2019-0022

Baümler, Marcel ; Gallant, Delphine ; Druckmann, Renã et al. / Ultrasound screening of ovarian cancer. In: Hormone Molecular Biology and Clinical Investigation. 2020 ; Vol. 41, No. 3.

@article{cc1c5d93763a4883aa07b726163a6f13,

title = "Ultrasound screening of ovarian cancer",

abstract = "Ovarian cancer has a high mortality rate. The most common serous type spreads rapidly throughout the peritoneal cavity when 5-year survival is 10%. If diagnosed in earlier stages where the cancer is still confined to the ovary, this survival rate is about 90%. This is the reason to be interested in screening at earlier stages in the average-risk general population. Thus, annual transvagin*l ultrasound (TVS) alone or as a multimodal screening test following serum carbohydrate antigen 125 (CA125) has been investigated. Ultrasound lacks sensitivity and specificity; new contrast-enhanced approaches might improve these. When the serum marker is combined with ultrasound and interpreted by a rise in the level rather than by a fixed cut-off, improved sensitivity and specificity and a late but not significant reduction in mortality are observed. Further investigations could highlight the interest of a shorter than annual screening, of a long-term follow-up and new contrast-enhanced ultrasound techniques.",

keywords = "Ovarian cancer, Screening, Ultrasound",

author = "Marcel Ba{\"u}mler and Delphine Gallant and Ren{\~a} Druckmann and Walther Kuhn",

note = "Publisher Copyright: {\textcopyright} 2019 Walter de Gruyter GmbH, Berlin/Boston.",

year = "2020",

month = sep,

day = "1",

doi = "10.1515/hmbci-2019-0022",

language = "English",

volume = "41",

journal = "Hormone Molecular Biology and Clinical Investigation",

issn = "1868-1883",

publisher = "Walter de Gruyter GmbH",

number = "3",

}

Baümler, M, Gallant, D, Druckmann, R 2020, 'Ultrasound screening of ovarian cancer', Hormone Molecular Biology and Clinical Investigation, vol. 41, no. 3, 20190022. https://doi.org/10.1515/hmbci-2019-0022

Ultrasound screening of ovarian cancer. / Baümler, Marcel; Gallant, Delphine; Druckmann, Renã et al.
In: Hormone Molecular Biology and Clinical Investigation, Vol. 41, No. 3, 20190022, 01.09.2020.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Ultrasound screening of ovarian cancer

AU - Baümler, Marcel

AU - Gallant, Delphine

AU - Druckmann, Renã

AU - Kuhn, Walther

N1 - Publisher Copyright:© 2019 Walter de Gruyter GmbH, Berlin/Boston.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Ovarian cancer has a high mortality rate. The most common serous type spreads rapidly throughout the peritoneal cavity when 5-year survival is 10%. If diagnosed in earlier stages where the cancer is still confined to the ovary, this survival rate is about 90%. This is the reason to be interested in screening at earlier stages in the average-risk general population. Thus, annual transvagin*l ultrasound (TVS) alone or as a multimodal screening test following serum carbohydrate antigen 125 (CA125) has been investigated. Ultrasound lacks sensitivity and specificity; new contrast-enhanced approaches might improve these. When the serum marker is combined with ultrasound and interpreted by a rise in the level rather than by a fixed cut-off, improved sensitivity and specificity and a late but not significant reduction in mortality are observed. Further investigations could highlight the interest of a shorter than annual screening, of a long-term follow-up and new contrast-enhanced ultrasound techniques.

AB - Ovarian cancer has a high mortality rate. The most common serous type spreads rapidly throughout the peritoneal cavity when 5-year survival is 10%. If diagnosed in earlier stages where the cancer is still confined to the ovary, this survival rate is about 90%. This is the reason to be interested in screening at earlier stages in the average-risk general population. Thus, annual transvagin*l ultrasound (TVS) alone or as a multimodal screening test following serum carbohydrate antigen 125 (CA125) has been investigated. Ultrasound lacks sensitivity and specificity; new contrast-enhanced approaches might improve these. When the serum marker is combined with ultrasound and interpreted by a rise in the level rather than by a fixed cut-off, improved sensitivity and specificity and a late but not significant reduction in mortality are observed. Further investigations could highlight the interest of a shorter than annual screening, of a long-term follow-up and new contrast-enhanced ultrasound techniques.

KW - Ovarian cancer

KW - Screening

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85075119484&partnerID=8YFLogxK

U2 - 10.1515/hmbci-2019-0022

DO - 10.1515/hmbci-2019-0022

M3 - Review article

C2 - 31661436

AN - SCOPUS:85075119484

SN - 1868-1883

VL - 41

JO - Hormone Molecular Biology and Clinical Investigation

JF - Hormone Molecular Biology and Clinical Investigation

IS - 3

M1 - 20190022

ER -

Baümler M, Gallant D, Druckmann R, Kuhn W. Ultrasound screening of ovarian cancer. Hormone Molecular Biology and Clinical Investigation. 2020 Sep 1;41(3):20190022. doi: 10.1515/hmbci-2019-0022